Form 4: Apellis Pharmaceuticals Chief Commercial Officer Sells Shares to Cover Tax Obligations

Adam J. Townsend, Chief Commercial Officer of Apellis Pharmaceuticals, sold 695 shares of common stock to cover tax withholding obligations related to restricted stock units.

Summary

• Adam J. Townsend, the Chief Commercial Officer of Apellis Pharmaceuticals, sold 695 shares of the company's common stock on January 29, 2025.
• The sale was executed at a price of $29.5236 per share.
• This transaction was to cover tax withholding obligations arising from the release of restricted stock units on January 28, 2025.
• Following the transaction, Townsend directly owns 84,050 shares of Apellis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment towards the company's performance or future prospects.

Industry Context

This is a routine transaction for company executives to manage their tax obligations related to stock-based compensation. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The volume of shares sold is relatively small compared to the total shares owned by the executive, which is typical for these types of transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the executive's confidence in the company.

Key Dates

Keywords

Apellis Pharmaceuticals, Adam J. Townsend, stock sale, insider trading, tax withholding, restricted stock units, APLS, Chief Commercial Officer